|
1
|
Wolmark N, Wang J, Mamonas E and Fisher B:
Preoperative chemotherapy in patients with operative breast cancer:
nine-year results from National Surgical Adjuvant Breast and Bowel
Project B-18. J Natl Cancer Inst Monogr. 30:96–102. 2001.
|
|
2
|
Bear HD, Anderson S, Brown A, et al: The
effect on tumor response of adding sequential preoperative
docetaxel to preoperative doxorubicin and cyclophosphamide:
preliminary results from National Surgical Adjuvant Breast and
Bowel Project B-27. J Crin Oncol. 21:4165–4174. 2003. View Article : Google Scholar
|
|
3
|
Smith IC, Heys SD, Hutcheon AW, et al:
Neoadjuvant chemotherapy in breast cancer: significantly enhanced
response with docetaxel. J Clin Oncol. 20:1456–1466. 2002.
View Article : Google Scholar
|
|
4
|
Ring AE, Smith IE, Ashley S, Fulford LG
and Lakhani SR: Oestrogen receptor status, pathological complete
response and prognosis in patients receiving neoadjuvant
chemotherapy for early breast cancer. Br J Cancer. 91:2012–2017.
2004. View Article : Google Scholar
|
|
5
|
Fasching PA, Heusinger K, Haeberle L, et
al: Ki67, chemotherapy response, and prognosis in breast cancer
patients receiving neoadjuvant treatment. BMC Cancer. 11:4862011.
View Article : Google Scholar
|
|
6
|
von Minckwitz G, Untch M, Blohmer JU, et
al: Definition and impact of pathologic complete response on
prognosis after neoadjuvant chemotherapy in various intrinsic
breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.PubMed/NCBI
|
|
7
|
Kawajiri H, Takashima T, Onoda N, et al:
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100
followed by weekly paclitaxel for operable breast cancer. Oncol
Lett. 4:612–616. 2012.PubMed/NCBI
|
|
8
|
Buzdar AU, Ibrahim NK, Francis D, et al:
Significantly higher pathologic complete remission rate after
neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin
chemotherapy: results of a randomized trial in human epidermal
growth factor receptor 2-positive operable breast cancer. J Clin
Oncol. 23:2676–2685. 2005. View Article : Google Scholar
|
|
9
|
The Japanese Breast Cancer Society.
General Rules for Clinical and Pathological Recording of Breast
Cancer. 16th edition. Kanehara Shuppan; pp. 602008
|
|
10
|
Wolff AC, Hammond ME, Schwartz JN, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar
|
|
11
|
Keskin S, Muslumanoglu M, Saip P, et al:
Clinical and pathological features of breast cancer associated with
the pathological complete response to anthracycline-based
neoadjuvant chemotherapy. Oncology. 81:30–38. 2011. View Article : Google Scholar
|
|
12
|
Tan MC, Al Mushawah F, Gao F, et al:
Predictors of complete pathological response after neoadjuvant
systemic therapy for breast cancer. Am J Surg. 198:520–525. 2009.
View Article : Google Scholar
|
|
13
|
Jones RL, Salter J, A’Hern R, et al:
Relationship between oestrogen receptor status and proliferation in
predicting response and long-term outcome to neoadjuvant
chemotherapy for breast cancer. Breast Cancer Res Treat.
119:315–323. 2010. View Article : Google Scholar
|
|
14
|
Colleoni M, Bagnardi V, Rotmensz N, et al:
Increasing steroid hormone receptors expression defines breast
cancer subtypes non responsive to preoperative chemotherapy. Breast
Cancer Res Treat. 116:359–369. 2009. View Article : Google Scholar
|
|
15
|
Toi M, Nakamura S, Kuroi K, et al: Phase
II study of preoperative sequential FEC and docetaxel predicts of
pathological response and disease free survival. Breast Cancer Res
Treat. 110:531–539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Buzdar AU, Valero V, Ibrahim NK, et al:
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil,
epirubicin, and cyclophosphamide chemotherapy and concurrent
trastuzumab in human epidermal growth factor receptor 2-positive
operable breast cancer: an update of the initial randomized study
population and data of additional patients treated with the same
regimen. Clin Cancer Res. 13:228–233. 2007.
|
|
17
|
Arimidex, Tamoxifen, Alone or in
Combination (ATAC) Trialists’ Group. Forbes JF, Cuzick J, et al:
Effect of anastrozole and tamoxifen as adjuvant treatment for
early-stage breast cancer: 100-month analysis of the ATAC trial.
Lancet Oncol. 9:45–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colleoni M, Giobbie-Hurder A, Regan MM, et
al: Analyses adjusting for selective crossover show improved
overall survival with adjuvant letrozole compared with tamoxifen in
the BIG1–98 study. J Clin Oncol. 29:1117–1124. 2011.
|
|
19
|
van de Velde CJ, Rea D, Seynaeve C, et al:
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a
randomised phase 3 trial. Lancet. 377:321–331. 2011.PubMed/NCBI
|
|
20
|
Gianni L, Dafni U, Gelber RD, et al:
Treatment with trastuzumab for 1 year after adjuvant chemotherapy
in patients with HER2-positive early breast cancer: a 4-year
follow-up of a randomised controlled trial. Lancet Oncol.
12:236–244. 2011.
|
|
21
|
Wolstenholme V, Hawkins M, Ashley S, Tait
D and Ross G: HER2 significance and treatment outcomes after
radiotherapy for brain metastases in breast cancer patients.
Breast. 17:661–665. 2008. View Article : Google Scholar
|
|
22
|
Aoyama H: Radiation therapy for brain
metastases in breast cancer patients. Breast Cancer. 18:244–251.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsumoto K, Ando M, Yamauchi C, et al:
Questionnaire survey of treatment choice for breast cancer patients
with brain metastasis in Japan: results of a nationwide survey by
the task force of the Japanese Breast Cancer Society. Jpn J Clin
Oncol. 39:22–26. 2009. View Article : Google Scholar
|
